Publications

Targeting GD2 with naxitamab overcomes GD3 synthase-driven immune suppression in triple-negative breast cancer

Download PDF
Resource: Targeting GD2 with naxitamab overcomes GD3 synthase-driven immune suppression in triple-negative breast cancer

.

Related Articles

Ultra-fast and automated immunohistofluorescent multistaining using a microfluidic tissue processor

Link
CREB5 promotes immunotherapy resistance via tumor-intrinsic collagen matrix deposition

Link